• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1%  SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Fever (1858); Viral Infection (2248)
Event Date 11/02/2020
Event Type  Injury  
Event Description
High fever [pyrexia].Cold [nasopharyngitis].Case narrative: case (b)(4) is a serious spontaneous case received from consumer via the fda in united states.This report concerns a patient (no patient identifiers reported) who experienced high fever and cold during treatment with intra-articular euflexxa (sodium hyaluronate) solution for injection unknown concentration and dose, for osteoarthritis from an unknown start date to an unknown stop date.The patient reported being hospitalized with a cold and high fever on (b)(6) 2020.The patient was hospitalized on an unspecified date in 2020 due to cold and high fever.Action taken with euflexxa was unknown.At the time of this report, the outcome of high fever and cold was unknown.Concomitant medication and medical history were not reported.All events in the case were reported as serious.At the time of reporting the case outcome was unknown.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: related.Other case numbers: internal # - others = mw5097907.Sender comment: despite of sodium hyaluronate's safety profile, a causal relationship between euflexxa's treatment and the event 'cold' cannot be ruled out, however, it is considered more likely that the fever is related to an infectious process, eg.A cold as reported and not to the product per se.This ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it does not meet the definition of a medical device incident according to the requirements of the medical device directive/ because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1%  SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
pob 571, be'er tuvia industria
l zone
kiryat malachi 83104 02
IS  8310402
MDR Report Key16438935
MDR Text Key310201185
Report Number0002244564-2021-00002
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)Y
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 02/24/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Event Location Other
Initial Date Manufacturer Received Not provided
Initial Date FDA Received02/24/2023
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage A
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
-
-